Pfizer Inc., of New York, said researchers presented new data for Elelyso (taliglucerase alfa) for injection to treat pediatric patients with type 1 Gaucher disease at the 11th Annual World Symposium in Orlando, Fla., including findings from a multicenter, phase III extension trial evaluating the long-term efficacy and safety of Elelyso in patients who were treatment-naïve or previously treated with imiglucerase.